2009 AAPM Meeting Spotlights Clinical, Physical Advantages of TomoTherapy® Platform

MADISON, Wis – August 5, 2009 – TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the 2009 meeting of the American Association of Physicists in Medicine (AAPM) featured a comprehensive look at the current and future role of TomoTherapy^® technology in addressing complex cancer treatment challenges. TomoTherapy users from around the world attended the AAPM annual meeting, presenting on topics that addressed: the successful use of TomoTherapy’s unique radiation therapy solution across a wide range of cases; planning studies documenting the clinical advantages of TomoTherapy over treatments from conventional radiation therapy devices; and investigations into radiobiological treatment improvements using the unique CT scanner-based TomoTherapy platform.

AAPM is the largest association of medical physicists in the world. The 2009 annual meeting was held in Anaheim, Calif., from July 26 to July 30. Below is a sampling of more than 50 TomoTherapy-related topics from the conference. For a comprehensive look at AAPM 2009 abstracts, download directory here.

• Biological Effect of Different IMRT Delivery Techniques: SMLC, DMLC and Helical TomoTherapy - Karmanos Cancer Center, Detroit, Mich., presented an analysis of various IMRT delivery techniques, including SMLC (step-and-shoot), DMLC (sliding window) and helical TomoTherapy. The purpose was to investigate the impact on cell survival of various temporal dose characteristics. The study finds helical TomoTherapy to be “biologically superior” to conventional techniques, based on reduced dose accumulation times for individual target elements (e.g. tumor cells).
• Dosimetric Characterization of Whole Brain Radiotherapy (WBRT) using Helical TomoTherapy - The Cancer Treatment and Research Center (CTRC), San Antonio, Tex., compared the dosimetric quality of TomoTherapy to conventional WBRT techniques. Results indicate that significant sparing of radiation exposure to the left and right eyes can be achieved when using TomoTherapy.
• Multicenter Intercomparison for Treatment of Mesothelioma with IMRT and TomoTherapy - Azienda Ospedaliero - Universitaria di Modena, Modena, Italy, evaluated TomoTherapy IMRT (intensity-modulated radiation therapy) against conventional linear accelerator-based techniques for the treatment of mesothelioma. The study reports that TomoTherapy is observed to allow better coverage and uniformity of dose to the target volume with better sparing of the nearby kidney and liver, in a faster treatment time.
• Treatment Planning Study of Epithelial Ovarian Cancers Using Helical TomoTherapy - Tata Memorial Centre, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Mumbai, India, assessed the use of TomoTherapy for Whole Abdomen Radiotherapy (WAR) of epithelial ovarian cancer. Their study states that TomoTherapy achieves excellent coverage of the WAR target with simultaneous pelvic boost and organ-at-risk sparing. The technique is being further evaluated in a phase II cohort study.

Said Fred Robertson, CEO of TomoTherapy: “AAPM is always an important meeting for TomoTherapy. This year’s conference showcased a strong body of work by our customers and research partners. We are pleased to see how our platform is being harnessed to advance cancer care.”

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

5 Aug 2009

• Recent Company News
• Company News Archives